Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Change in Account Payables: 2022-2025

Historic Change in Account Payables for bioAffinity Technologies (BIAF) over the last 4 years, with Sep 2025 value amounting to -$229,076.

  • bioAffinity Technologies' Change in Account Payables fell 251.53% to -$229,076 in Q3 2025 from the same period last year, while for Sep 2025 it was $157,823, marking a year-over-year increase of 164.90%. This contributed to the annual value of $382,521 for FY2024, which is 2737.89% up from last year.
  • bioAffinity Technologies' Change in Account Payables amounted to -$229,076 in Q3 2025, which was down 8.19% from -$211,741 recorded in Q2 2025.
  • Over the past 5 years, bioAffinity Technologies' Change in Account Payables peaked at $577,474 during Q3 2023, and registered a low of -$435,285 during Q3 2022.
  • Its 3-year average for Change in Account Payables is $29,225, with a median of -$65,165 in 2024.
  • In the last 5 years, bioAffinity Technologies' Change in Account Payables crashed by 1,248.49% in 2023 and then spiked by 1,565.44% in 2024.
  • bioAffinity Technologies' Change in Account Payables (Quarterly) stood at $195,360 in 2022, then crashed by 315.67% to -$421,337 in 2023, then spiked by 148.51% to $204,373 in 2024, then slumped by 251.53% to -$229,076 in 2025.
  • Its last three reported values are -$229,076 in Q3 2025, -$211,741 for Q2 2025, and $394,267 during Q1 2025.